Neurodegeneration research leader arrives

Ray to drive quest for new Alzheimer's disease therapies

BY Sarah Watson

Jim Ray, Ph.D.

Jim Ray, Ph.D., has joined MD Anderson’s Institute for Applied Cancer Science as head of research for the Neurodegeneration Consortium (NDC), a collaboration among MD Anderson, Baylor College of Medicine and the Massachusetts Institute of Technology.

Ray has extensive experience in the pharmaceutical and biotech industries, focusing on Alzheimer’s disease, schizophrenia, Parkinson’s disease, and endocrine and metabolic disorders. Formerly director at Takeda Pharmaceutical’s CNS Research, he’s responsible for coordinating NDC efforts and collaborating with drug discovery scientists at the Institute for Applied Cancer Science to bring innovative therapies to patients with neurodegenerative disease.

More Stories From Promise

A message from Dr. DePinho

A word from the president

PUTTing an end to cancer

The world of professional golf is laden with hazards, from fairway bunkers to sand traps and ponds. MD Anderson is partnering with the PGA TOUR in hopes of fighting one of the most dangerous hazards of them all: the sun.

Home team advantage

Three-time survivor finds hope in MD Anderson care, support

Moon Shots Program Overview

MD Anderson's Moon Shots Program is an unprecedented, comprehensive assault to significantly reduce deaths from cancer.

iPromise

Corky Hilliard, of Austin, is a tongue cancer survivor and the founder of Hilliard Resources, an organizational strategies and consulting company. Active in her community, Hilliard passionately defends the rights of the homeless. Here, she reflects on the inner peace she found at MD Anderson.

Survivors Say

Perry Rupp, of Roanoke, Texas, was diagnosed with multiple myeloma and underwent a stem cell transplant in 2012. Today, you’ll find him hiking, biking and driving his RV cross country, visiting as many national parks as possible along the way. He credits his recovery to the incredible doctors and nurses at MD Anderson.